Targeted therapy for patients whose tumors harbor the BRAFV600 mutation achieves high response rates and OS benefit with the combination BRAF/MEK inhibition and represents the ideal first-line treatment for patients with BRAF-mutated advanced melanoma. The gene discussed is BRAF; the disease is melanoma.